NEW HOPE AGAINST PROSTATE CANCER: PLUVICTO RADIOLIGAND THERAPY REDUCES THE RISK OF DISEASE PROGRESSION BY 28%

A groundbreaking targeted therapy could change the future of prostate cancer treatment. Pluvicto™ (177Lu-PSMA-617), developed by Novartis, is a radioligand therapy that combines a molecule designed to locate tumor cells with a radioactive isotope that destroys them from within.

In the international Phase III clinical trial known as PSMAddition, researchers compared standard therapy (androgen deprivation and hormone-blocking drugs) with the same regimen plus Pluvicto in patients with metastatic hormone-sensitive prostate cancer.
The results were clear: men who received Pluvicto experienced a 28% lower risk of disease progression or death during the follow-up period.

The secret lies in its precision. The radioligand targets cells that express PSMA, a protein highly present in prostate cancer cells, and delivers a lethal dose of radiation directly to them, while sparing healthy tissues.

Although overall survival data are still being collected, experts believe this approach could move into earlier stages of metastatic prostate cancer and significantly improve patients’ quality and length of life.

Pluvicto is already used in some countries for more advanced cases, and this new study suggests that its early use could soon become part of the standard treatment protocol.

A development that brings new hope to millions of men worldwide and marks another step forward in precision medicine.